Edition:
India

GW Pharmaceuticals PLC (GWPH.OQ)

GWPH.OQ on NASDAQ Stock Exchange Global Market

146.22USD
20 Jul 2018
Change (% chg)

$-2.39 (-1.61%)
Prev Close
$148.61
Open
$148.09
Day's High
$148.65
Day's Low
$145.20
Volume
96,332
Avg. Vol
105,915
52-wk High
$164.58
52-wk Low
$96.43

Latest Key Developments (Source: Significant Developments)

FDA Approves Epidiolex (Cannabidiol) Oral Solution To Treat Rare, Severe Forms Of Epilepsy
Monday, 25 Jun 2018 

June 25 (Reuters) - U.S. Food and Drug Administration::U.S. FDA - APPROVED EPIDIOLEX (CANNABIDIOL) ORAL SOLUTION FOR TREATMENT OF SEIZURES ASSOCIATED WITH 2 SEVERE FORMS OF EPILEPSY IN PATIENTS 2 YRS & OLDER.U.S. FDA - FDA GRANTED APPROVAL OF EPIDIOLEX TO GW RESEARCH LTD.U.S. FDA - EPIDIOLEX APPROVED FOR TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME & DRAVET SYNDROME IN PATIENTS 2 YRS & OLDER.  Full Article

GW Pharmaceuticals Reacquires Full Rights To Develop And Commercialize Sativex In U.S.
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - GW Pharmaceuticals Plc ::GW PHARMACEUTICALS REACQUIRES FULL RIGHTS TO DEVELOP AND COMMERCIALIZE SATIVEX® IN U.S..GW PHARMACEUTICALS - NOW REACQUIRED FULL OWNERSHIP OF DEVELOPMENT, COMMERCIALIZATION RIGHTS TO PRODUCT IN U.S. WITHOUT UPFRONT PAYMENT TO OTSUKA​.GW PHARMACEUTICALS - ‍AGREED TO MAKE CONTINGENT MILESTONE PAYMENTS TO OTSUKA, FIRST OF WHICH WOULD BECOME DUE UPON FDA APPROVAL OF SATIVEX​.GW PHARMACEUTICALS PLC - ‍TERMINATION OF PREVIOUS LICENSE AGREEMENT WITH OTSUKA PHARMACEUTICAL CO IN RELATION TO SATIVEX IN U.S.​.  Full Article

GW Pharmaceuticals Announces Proposed Public Offering Of ADSs
Wednesday, 6 Dec 2017 

Dec 5 (Reuters) - Gw Pharmaceuticals Plc ::GW PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS.GW PHARMACEUTICALS PLC - INTENDS TO SELL $225 MILLION OF AMERICAN DEPOSITARY SHARES.  Full Article

GW Pharma says second positive phase 3 trial for epidiolex in LGS
Monday, 26 Sep 2016 

Gw Pharmaceuticals Plc : Second positive phase 3 trial for Epidiolex in LGS . Primary endpoint achieved in both Epidiolex doses with high statistical significance compared to placebo . Expects to submit a new drug application to U.S. Food & Drug Administration in first half of 2017. . Data represents third positive phase 3 pivotal trial for epidiolex reported in 2016 . Second positive phase 3 pivotal trial for epidiolex cannabidiol in treatment of Lennox-Gastaut Syndrome .During treatment period, patients taking epidiolex 20mg/kg/day achieved median reduction in monthly drop seizures of 42 percent.  Full Article

GW Pharmaceuticals Q3 rev down sharply as Sativex R&D fees falls
Tuesday, 9 Aug 2016 

GW Pharmaceuticals Plc : 3Rd quarter results . Positive FDA pre-NDA meeting - NDA for dravet syndrome and LGS on track for h1 2017 submission . Loss for nine months ended 30 June 2016 of £46.7 million ($62.2 million) compared to £32.3 million for nine months ended 30 June 2015 . Cash and cash equivalents at 30 June 2016 of £191.2 million ($254.3 million) compared to £234.9 million as at 30 september 2015 . Plans to continue expansion of epidiolex plant growing capacity well beyond this 2016 goal . Total revenue for three months to 30 June 2016 was £2.3 million, compared to £8.6 million for three months ended 30 June 2015 . Remains on track to meet expenditure guidance given with its Q2 results in May 2016 . Exchange rate gain of £11.2 million experienced in Q3 has reduced projected net cash outflow for 2016 financial year .Subject to further exchange rate related volatility group's Q4 expenditure plans remain consistent with previous guidance.  Full Article

GW Pharmaceuticals says chief medical officer to retire
Tuesday, 9 Aug 2016 

Gw Pharmaceuticals Plc : Stephen Wright has notified GW's board of directors of his intention to retire .Wright plans to step down from his position as chief medical officer and a member of board of directors on 1 May 2017.  Full Article

UPDATE 2-Zogenix's seizure drug clears late-stage trial, shares soar

July 12 Zogenix Inc said on Thursday its drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer's shares up as much as 26 percent.